DossierENTITY

Sam Fazeli

Coverage of Sam Fazeli in the Nexus archive.

Earliest in view: Aug 3 · 16:37 UTCMost recent: Aug 3 · 16:37 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSAug 3 · 16:37 UTCBLOOMBERG
AstraZeneca Investors See Little Logic in Bristol Tie-Up
AstraZeneca Plc investors expressed disapproval of a proposed $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Sam Fazeli discussed the reaction to the deal.